12 results on '"Tjong FV"'
Search Results
2. End-of-life Management of Leadless Cardiac Pacemaker Therapy.
- Author
-
Beurskens NE, Tjong FV, and Knops RE
- Abstract
The clinically available leadless pacemakers for patients with a single-chamber pacing indication have shown to be safe and effective. However, the optimal end-of-life strategy of this novel technique is undefined. Suggested strategies comprise of (a) placing an additional leadless device adjacent to the leadless pacemaker, or (b) retrieving the non-functioning leadless pacemaker and subsequently implanting a new device. Although initial studies demonstrate promising results, early experience of acute and mid-term retrieval feasibility and safety remains mixed. We suggest that the approach of leadless pacemaker retrieval is more appealing to limit the amount of non-functioning intracardiac hardware. In addition, potential risks for device-device interference, and unknown long-term complications associated with multiple intracardiac devices are prevented. The potential inability to retrieve chronically implanted leadless pacemakers limits the application of this novel technology. Therefore, long-term prospective analysis is required to define the most optimal end-of-life strategy., Competing Interests: Disclosure: Dr Beurskens has nothing to declare. Dr Tjong reports consulting fees from Boston Scientific and Abbott. Dr Knops reports consulting fees, research grants and honoraria for Boston Scientific, and consulting fees and research grants with Medtronic and Abbott.
- Published
- 2017
- Full Text
- View/download PDF
3. Permanent Leadless Cardiac Pacemaker Therapy: A Comprehensive Review.
- Author
-
Tjong FV and Reddy VY
- Subjects
- Clinical Trials as Topic, Education, Medical, Continuing, Humans, Treatment Outcome, Arrhythmias, Cardiac therapy, Cardiac Pacing, Artificial adverse effects, Cardiac Pacing, Artificial methods, Pacemaker, Artificial
- Abstract
A new technology, leadless pacemaker therapy, was recently introduced clinically to address lead- and pocket-related complications in conventional transvenous pacemaker therapy. These leadless devices are self-contained right ventricular single-chamber pacemakers implanted by using a femoral percutaneous approach. In this review of available clinical data on leadless pacemakers, early results with leadless devices are compared with historical results with conventional single-chamber pacing. Both presently manufactured leadless pacemakers show similar complications, which are mostly related to the implant procedure: cardiac perforation, device dislocation, and femoral vascular access site complications. In comparison with conventional transvenous single-chamber pacemakers, slightly higher short-term complication rates have been observed: 4.8% for leadless pacemakers versus 4.1% for conventional pacemakers. The complication rate of the leadless pacemakers is influenced by the implanter learning curve for this new procedure. No long-term outcome data are yet available for the leadless pacemakers. Larger leadless pacing trials, with long-term follow-up and direct randomized comparison with conventional pacing systems, will be required to define the proper clinical role of these leadless systems. Although current leadless pacemakers are limited to right ventricular pacing, future advanced, communicating, multicomponent systems are expected to expand the potential benefits of leadless therapy to a larger patient population., (© 2017 American Heart Association, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
4. Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance.
- Author
-
Tjong FV, Brouwer TF, Smeding L, Kooiman KM, de Groot JR, Ligon D, Sanghera R, Schalij MJ, Wilde AA, and Knops RE
- Subjects
- Aged, Aged, 80 and over, Animals, Combined Modality Therapy, Electrocardiography, Equipment Design, Follow-Up Studies, Humans, Male, Netherlands, Sheep, Treatment Outcome, Arrhythmias, Cardiac therapy, Defibrillators, Implantable standards, Electric Countershock instrumentation, Pacemaker, Artificial standards
- Abstract
Aims: The subcutaneous implantable cardioverter-defibrillator (S-ICD) and leadless pacemaker (LP) are evolving technologies that do not require intracardiac leads. However, interactions between these two devices are unexplored. We investigated the feasibility, safety, and performance of combined LP and S-ICD therapy, considering (i) simultaneous device-programmer communication, (ii) S-ICD rhythm discrimination during LP communication and pacing, and (iii) post-shock LP performance., Methods and Results: The study consists of two parts. Animal experiments: Two sheep were implanted with both an S-ICD and LP (Nanostim, SJM), and the objectives above were tested. Human experience: Follow-up of one S-ICD patient with bilateral subclavian occlusion who received an LP and two LP (all Nanostim, SJM) patients (without S-ICD) who received electrical cardioversion (ECV) are presented. Animal experiments : Simultaneous device-programmer communication was successful, but LP-programmer communication telemetry was temporarily lost (2 ± 2 s) during ventricular fibrillation (VF) induction and 4/54 shocks. Leadless pacemaker communication and pacing did not interfere with S-ICD rhythm discrimination. Additionally, all VF episodes (n = 12/12), including during simultaneous LP pacing, were detected and treated by the S-ICD. Post-shock LP performance was unaltered, and no post-shock device resets or dislodgements were observed (24 S-ICD and 30 external shocks). Human experience : The S-ICD/LP patient showed adequate S-ICD sensing during intrinsic rhythm, nominal, and high-output LP pacing. Two LP patients (without S-ICD) received ECV during follow-up. No impact on performance or LP dislodgements were observed., Conclusion: Combined LP and S-ICD therapy appears feasible in all animal experiments (n = 2) and in one human subject. No interference in sensing and pacing during intrinsic and paced rhythm was noted in both animal and human subjects. However, induced arrhythmia testing was not performed in the patient. Defibrillation therapy did not seem to affect LP function. More data on safety and performance are needed., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016. For permissions please email: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
5. Postmortem Histopathological Examination of a Leadless Pacemaker Shows Partial Encapsulation After 19 Months.
- Author
-
Tjong FV, Stam OC, van der Wal AC, Beenen LF, Bouma BJ, de Groot JR, Wilde AA, and Knops RE
- Subjects
- Aged, 80 and over, Autopsy, Device Removal, Echocardiography, Transesophageal, Fatal Outcome, Fibrosis, Humans, Male, Time Factors, Tomography, X-Ray Computed, Pacemaker, Artificial, Tissue Adhesions pathology
- Published
- 2015
- Full Text
- View/download PDF
6. State of the art of leadless pacing.
- Author
-
Sperzel J, Burri H, Gras D, Tjong FV, Knops RE, Hindricks G, Steinwender C, and Defaye P
- Subjects
- Equipment Design, Humans, Prostheses and Implants, Treatment Outcome, Cardiac Catheters adverse effects, Cardiac Resynchronization Therapy Devices adverse effects, Cardiac Resynchronization Therapy Devices classification, Endocardium physiopathology, Heart Ventricles physiopathology
- Abstract
Despite undisputable benefits, conventional pacemaker therapy is associated with specific complications related to the subcutaneous device and the transvenous leads. Recently, two miniaturized leadless pacemakers, Nanostim™ (St. Jude Medical) and Micra™ (Medtronic), which can be completely implanted inside the right ventricle using steerable delivery systems, entered clinical application. The WiCS™-cardiac resynchronisation therapy (CRT) system (wireless cardiac stimulation for CRT, EBR Systems) delivers leadless left ventricular endocardial stimulation for cardiac resynchronization. In addition to obvious cosmetic benefits, leadless pacing systems may have the potential to overcome some complications of conventional pacing. However, acute and long-term complications still remains to be determined, as well as the feasibility of device explantation years after device placement., (© The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2015
- Full Text
- View/download PDF
7. A leadless solution.
- Author
-
Tjong FV, Kooiman KM, de Groot JR, and Knops RE
- Subjects
- Aged, Anti-Bacterial Agents therapeutic use, Equipment Design, Humans, Male, Prosthesis-Related Infections diagnosis, Prosthesis-Related Infections microbiology, Recurrence, Reoperation, Risk Factors, Treatment Outcome, Cardiac Pacing, Artificial, Device Removal, Pacemaker, Artificial adverse effects, Prosthesis-Related Infections therapy
- Published
- 2015
- Full Text
- View/download PDF
8. Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS trial.
- Author
-
Knops RE, Tjong FV, Neuzil P, Sperzel J, Miller MA, Petru J, Simon J, Sediva L, de Groot JR, Dukkipati SR, Koruth JS, Wilde AA, Kautzner J, and Reddy VY
- Subjects
- Aged, Cardiac Pacing, Artificial, Equipment Design, Equipment Safety, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Arrhythmias, Cardiac therapy, Pacemaker, Artificial
- Abstract
Background: A leadless cardiac pacemaker (LCP) system was recently introduced to overcome lead-related complications of conventional pacing systems. To date, long-term results of an LCP system are unknown., Objectives: The aim of this study was to assess the complication incidence, electrical performance, and rate response characteristics within the first year of follow-up of patients implanted with an LCP., Methods: We retrospectively assessed intermediate-term follow-up data for 31 of 33 patients from the LEADLESS trial cohort who had an indication for single-chamber pacing and received an LCP between December 2012 and April 2013., Results: The mean age of the cohort was 76 ± 8 years, and 65% were male. Between 3 and 12 months of follow-up, there were no pacemaker-related adverse events reported. The pacing performance results at 6- and 12-month follow-up were, respectively, as follows: mean pacing threshold (at a 0.4-ms pulse width), 0.40 ± 0.26 V and 0.43 ± 0.30 V; R-wave amplitude 10.6 ± 2.6 mV and 10.3 ± 2.2 mV; and impedance 625 ± 205 Ω and 627 ± 209 Ω. At the 12-month follow-up in 61% of the patients (n = 19 of 31), the rate response sensor was activated, and an adequate rate response was observed in all patients., Conclusions: The LCP demonstrates very stable performance and reassuring safety results during intermediate-term follow-up. These results support the use of the LCP as a promising alternative to conventional pacemaker systems. Continued evaluation is warranted to further characterize this system. (Evaluation of a New Cardiac Pacemaker; NCT01700244)., (Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
9. Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients.
- Author
-
Zhang Y, Guallar E, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S, Tjong FV, Eldadah Z, Dickfeld T, Ellenbogen KA, Marine JE, Tomaselli GF, and Cheng A
- Subjects
- Aged, Creatine Kinase, MB Form blood, Death, Sudden, Cardiac epidemiology, Female, Heart Failure mortality, Heart Failure therapy, Humans, Incidence, Male, Middle Aged, Natriuretic Peptide, Brain blood, Netherlands epidemiology, Peptide Fragments blood, Prognosis, Prospective Studies, Protein Precursors, Risk Factors, Survival Rate trends, Troponin T blood, United States epidemiology, Biomarkers blood, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Heart Failure blood, Primary Prevention methods, Risk Assessment
- Abstract
Background: Implantable cardioverter-defibrillator (ICD) implantation is contraindicated in those with <1-year life expectancy., Objectives: The aim of this study was to develop a risk prediction score for 1-year mortality in patients with primary prevention ICDs and to determine the incremental improvement in discrimination when serum-based biomarkers are added to traditional clinical variables., Methods: We analyzed data from the Prospective Observational Study of Implantable Cardioverter-Defibrillators, a large prospective observational study of patients undergoing primary prevention ICD implantation who were extensively phenotyped for clinical and serum-based biomarkers. We identified variables predicting 1-year mortality and synthesized them into a comprehensive risk scoring construct using backward selection., Results: Of 1189 patients deemed by their treating physicians as having a reasonable 1-year life expectancy, 62 (5.2%) patients died within 1 year of ICD implantation. The risk score, composed of 6 clinical factors (age ≥75 years, New York Heart Association class III/IV, atrial fibrillation, estimated glomerular filtration rate <30 mL/min/1.73 m(2), diabetes, and use of diuretics), had good discrimination (area under the curve 0.77) for 1-year mortality. Addition of 3 biomarkers (tumor necrosis factor α receptor II, pro-brain natriuretic peptide, and cardiac troponin T) further improved model discrimination to 0.82. Patients with 0-1, 2-3, 4-6, or 7-9 risk factors had 1-year mortality rates of 0.8%, 2.7%, 16.1%, and 46.2%, respectively., Conclusion: Individuals with more comorbidities and elevation of specific serum biomarkers were at increased risk of all-cause mortality despite being deemed as having a reasonable 1-year life expectancy. A simple risk score composed of readily available clinical data and serum biomarkers may better identify patients at high risk of early mortality and improve patient selection and counseling for primary prevention ICD therapy., (Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
10. Permanent leadless cardiac pacing: results of the LEADLESS trial.
- Author
-
Reddy VY, Knops RE, Sperzel J, Miller MA, Petru J, Simon J, Sediva L, de Groot JR, Tjong FV, Jacobson P, Ostrosff A, Dukkipati SR, Koruth JS, Wilde AA, Kautzner J, and Neuzil P
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Feasibility Studies, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Postoperative Complications epidemiology, Prospective Studies, Treatment Outcome, Arrhythmias, Cardiac therapy, Equipment Design, Pacemaker, Artificial
- Abstract
Background: Conventional cardiac pacemakers are associated with several potential short- and long-term complications related to either the transvenous lead or subcutaneous pulse generator. We tested the safety and clinical performance of a novel, completely self-contained leadless cardiac pacemaker., Methods and Results: The primary safety end point was freedom from complications at 90 days. Secondary performance end points included implant success rate, implant time, and measures of device performance (pacing/sensing thresholds and rate-responsive performance). The mean age of the patient cohort (n=33) was 77±8 years, and 67% of the patients were male (n=22/33). The most common indication for cardiac pacing was permanent atrial fibrillation with atrioventricular block (n=22, 67%). The implant success rate was 97% (n=32). Five patients (15%) required the use of >1 leadless cardiac pacemaker during the procedure. One patient developed right ventricular perforation and cardiac tamponade during the implant procedure, and eventually died as the result of a stroke. The overall complication-free rate was 94% (31/33). After 3 months of follow-up, the measures of pacing performance (sensing, impedance, and pacing threshold) either improved or were stable within the accepted range., Conclusions: In a prospective nonrandomized study, a completely self-contained, single-chamber leadless cardiac pacemaker has shown to be safe and feasible. The absence of a transvenous lead and subcutaneous pulse generator could represent a paradigm shift in cardiac pacing., Clinical Trial Registration Url: http://clinicaltrials.gov. Unique identifier: NCT01700244.
- Published
- 2014
- Full Text
- View/download PDF
11. Mild-to-moderate kidney dysfunction and the risk of sudden cardiac death in the setting of acute myocardial infarction.
- Author
-
Dalal D, de Jong JS, Tjong FV, Wang Y, Bruinsma N, Dekker LR, and Wilde AA
- Subjects
- Case-Control Studies, Chi-Square Distribution, Confidence Intervals, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac etiology, Female, Glomerular Filtration Rate, Health Status Indicators, Heart Arrest epidemiology, Heart Arrest etiology, Humans, Logistic Models, Male, Middle Aged, Myocardial Infarction etiology, Odds Ratio, Risk, Death, Sudden, Cardiac pathology, Heart Arrest pathology, Kidney pathology, Kidney Diseases pathology, Myocardial Infarction epidemiology, Myocardial Infarction pathology, Tachycardia, Ventricular pathology
- Abstract
Background: Although end-stage renal disease is known to elevate the risk of sudden cardiac death (SCD), the role of less severe renal impairment in SCD is unclear., Objective: The purpose of this study was to examine the association between mild-to-moderate renal impairment and first ischemic ventricular fibrillation (VF)., Methods: Renal function in patients included in the Arrhythmia Genetics in the NEtherlands Study (AGNES) were compared. Cases (n = 337, age 56 ± 1 year, 80% men) were defined as patients who had survived VF at the time of their first acute ST elevation myocardial infarction (STEMI), and controls (n = 339, age 58 ± 1 years, 80% men) were defined as those without VF during their first acute STEMI. Estimated glomerular filtration rate (eGFR) at the time of acute STEMI was computed using the 4-variable Modification of Diet in Renal Disease equation., Results: At eGFR less than 105 mL/min, a decrease in eGFR was associated with elevated odds of developing VF during STEMI. The association was essentially flat at eGFR levels >105 mL/min. The lowest eGFR quintile was associated with a >6-fold increase in odds of developing VF compared to the fourth quintile. This association between eGFR and VF at the time of STEMI remained significant after adjusting for potential confounders including electrolyte levels., Conclusion: Mild-to-moderate kidney dysfunction is associated with a significantly elevated risk of VF in the setting of acute STEMI. Further studies are needed to investigate the precise mechanisms by which mild kidney function results in VF., (Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
12. Plasma glucose and not hemoglobin or renal function predicts mortality in patients with STEMI complicated with cardiogenic shock.
- Author
-
Vis MM, Engström AE, Sjauw KD, Tjong FV, Baan J Jr, Koch KT, DeVries JH, Tijssen JG, de Winter RJ, Piek JJ, and Henriques JP
- Subjects
- Aged, Anemia blood, Anemia complications, Angioplasty, Balloon, Coronary mortality, Biomarkers blood, Chi-Square Distribution, Female, Humans, Hyperglycemia blood, Hyperglycemia complications, Kidney metabolism, Logistic Models, Male, Middle Aged, Myocardial Infarction blood, Myocardial Infarction complications, Myocardial Infarction physiopathology, Myocardial Infarction therapy, Netherlands, Odds Ratio, Patient Admission, Prospective Studies, Registries, Risk Assessment, Risk Factors, Shock, Cardiogenic blood, Shock, Cardiogenic etiology, Shock, Cardiogenic physiopathology, Time Factors, Treatment Outcome, Anemia mortality, Blood Glucose metabolism, Creatinine blood, Hemoglobins metabolism, Hyperglycemia mortality, Kidney physiopathology, Myocardial Infarction mortality, Shock, Cardiogenic mortality
- Abstract
Objective: To assess the predictive value of three biomarkers for mortality in ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock., Background: STEMI complicated by cardiogenic shock accounts for the majority of STEMI related deaths. Patients with STEMI and hyperglycemia, anemia or kidney dysfunction on admission have a poor prognosis. As data on the combination of those three established predictors of mortality are sparse in STEMI with cardiogenic shock, the objective of the current study was to investigate their predictive value in STEMI patients with cardiogenic shock., Methods and Results: Between 1997 and 2005, a total of 3038 patients presented with STEMI and were treated with percutaneous coronary intervention (PCI). On admission 292 patients presented with cardiogenic shock. Glucose, hemoglobin and creatinine clearance were available in 183 out of 292 patients. Overall 1-year mortality was 34%. In multivariate logistic regression analysis, only glucose remained a strong independent predictor for mortality. The odds for mortality increased by 11% for each 1 mmol/l increase in glucose (OR 1.11, 95% CI 1.02-1.21, P = 0.013)., Conclusion: Hemoglobin and creatinine clearance bear no prognostic value. Only admission glucose levels strongly and independently predict 1-year mortality in STEMI patients with cardiogenic shock and treated with PCI.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.